SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
Saved in:
| Title: | SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. |
|---|---|
| Authors: | Ferreira IATM; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom., Kemp SA; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom., Datir R; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom., Saito A; Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki,Japan., Meng B; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom., Rakshit P; National Centre for Disease Control, Delhi,India., Takaori-Kondo A; Department of Hematology and Oncology, Kyoto University, Kyoto,Japan., Kosugi Y; Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan., Uriu K; Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan., Kimura I; Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan., Shirakawa K; Department of Hematology and Oncology, Kyoto University, Kyoto,Japan., Abdullahi A; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom., Agarwal A; CSIR Institute of Genomics and Integrative Biology, Delhi,India., Ozono S; Department of Pathology, National Institute of Infectious Diseases, Tokyo,Japan., Tokunaga K; Department of Pathology, National Institute of Infectious Diseases, Tokyo,Japan., Sato K; Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.; CREST , Japan Science and Technology Agency, Saitama,Japan., Gupta RK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom.; Department of Medicine, University of Cambridge, Cambridge,United Kingdom.; Africa Health Research Institute, Durban,South Africa. |
| Corporate Authors: | CITIID-NIHR BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium, Genotype to Phenotype Japan (G2P-Japan) Consortium |
| Source: | The Journal of infectious diseases [J Infect Dis] 2021 Sep 17; Vol. 224 (6), pp. 989-994. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
